期刊文献+

他达拉非纳米晶体干混悬剂的制备与质量评价 被引量:2

Preparation and quality evaluation of Tadalafil Nanocrystal Dry Suspensions
下载PDF
导出
摘要 目的制备他达拉非纳米晶体干混悬剂,并评价其质量。方法采用介质研磨法将他达拉非制备成纳米晶体,通过喷雾干燥工艺固化成固体颗粒,并与其他辅料混合后制备成干混悬剂;以沉降体积比和再分散性作为评价指标,通过单因素实验筛选干混悬剂中填充剂和助悬剂的种类及用量;通过扫描电镜观察他达拉非原料药、固化前后的纳米晶体颗粒以及干混悬剂的微观结构;比较他达拉非纳米晶体干混悬剂与市售他达拉非片剂的体外药物溶出速率。结果经实验优化得到他达拉非纳米晶体干混悬剂的处方组成为:填充剂甘露醇用量为40%,助悬剂黄原胶用量为25%;固化前后他达拉非纳米晶体的粒径分布未发生显著变化;在扫描电镜下可以观察到他达拉非原料药呈片状或柱状分布,纳米晶体呈不规则颗粒状分布,喷雾干燥后呈疏松粉末状;与他达拉非片相比,他达拉非纳米晶体干混悬剂药物溶出速度更快,在10 min内药物可完全溶出。结论将他达拉非制备成纳米晶体干混悬剂,处方设计合理,工艺可行,药物溶出速率显著提高,有望提高生物利用度。 Objective To prepare Tadalafil Nanocrystal Dry Suspensions and evaluate the preparation quality.Methods The tadalafil nanocrystal was prepared by wet media milling method,which was solidified into solid particles through a spray drying process,and mixed with other excipients to prepare dry suspensions.The types and amount of filler and suspending agent in dry suspensions were determined by single factor experiment.Scanning electron microscopy was used to observe the microstructure of tadalafil nanocrystal before and after being solidified and in dry suspensions.The in vitro drug dissolution rates of Tadalafil Nanocrystal Dry Suspensions and commercial Tadalafil Tablets were compared.Results The formulation of Tadalafil Nanocrystal Dry Suspensions was as follows:the amount of mannitol 40%,and the amount of xanthan gum 25%.The particle size distribution of tadalafil nanocrystal did not change significantly before and after being solidified.Under scanning electron microscopy,it was observed that tadalafil was distributed in plate-like,the nanocrystal was distributed in irregular particles,and the spray-dried particles was loose powder.Compared with Tadalafil Tablets,Tadalafil Nanocrystal Dry Suspensions had a faster dissolution rate,and the drug could be completely dissolved within 10 min.Conclusion Tadalafil was prepared as a nanocrystal dry suspensions.The formulation design was reasonable and the process was feasible.The drug dissolution rate was significantly improved,and therefore the drug bioavailability is expected to be improved.
作者 李永 蔡文婷 LI Yong;CAI Wenting(Department of Pharmacy,Wuhan Red Cross Hospital,Wuhan 430015,China;Department of Geriatrics,Wuhan Red Cross Hospital,Wuhan 430015,China)
出处 《西北药学杂志》 CAS 2021年第3期434-439,共6页 Northwest Pharmaceutical Journal
关键词 他达拉非 纳米晶体 干混悬剂 介质研磨法 黄原胶 溶出度 tadalafil nanocrystal dry suspensions wet media milling method xanthan gum dissolution
  • 相关文献

参考文献7

二级参考文献103

  • 1周前贵,冯高闳.槐果碱的降压作用及其机制[J].中国药理学通报,1989,5(6):358-362. 被引量:5
  • 2王亚群,祝秀珍,陈永志.HPLC法测定注射用夫西地酸钠的含量[J].中国医药指南,2008,6(18). 被引量:6
  • 3黄成栋,白雪芳,杜昱光.黄原胶(Xanthan Gum)的特性、生产及应用[J].微生物学通报,2005,32(2):91-98. 被引量:49
  • 4张贤生,王益鑫,黄旭元,冷静,李铮,韩银发.西地那非、舍曲林合用与舍曲林单用治疗早泄的疗效比较[J].中华男科学杂志,2005,11(7):520-522. 被引量:18
  • 5崔福德.药剂学[M].第5版.北京:人民卫生出版社,2006:244-245.
  • 6严瑞喧.水溶性高分子[M].第1版.北京:化学工业出版社,1998:498-499.
  • 7Otunctemur A,Ozbek E,Kirecci SL,et al.Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation:Decreased nitric oxide is associated with premature ejaculation.Andrologia,2014,46(9):951-955.
  • 8Gao J,Zhang X,Su P,et al.Prevalence and factors associated with the complaint of premature ejaculation and the four premature ejaculation syndromes:A large observational study in China.J Sex Med,2013,10(7):1874-1881.
  • 9Mc Mahon CG,Jannini E,Waldinger M,et al.Standard operating procedures in the disorders of orgasm and ejaculation.J Sex Med,2013,10(1):204-229.
  • 10Asimakopoulos AD,Miano R,Finazzi AgròE.Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation?A systematic review and meta-analysis.J Sex Med,2012,9(9):2404-2416.

共引文献63

同被引文献11

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部